A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S DISEASE PATIENTS

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

1. To evaluate safety, tolerability and pharmacokinetics of multiple doses of PF-04360365 administered monthly (approximately every 30 days; Cohort M) or every 3 months (approximately every 90 days; Cohort Q) for approximately one year in subjects with mild-to-moderate AD. 2. To assess the effect of multiple doses of PF-04360365 on brain amyloid burden in the subjects dosed monthly (Cohort M) for approximately one year in subjects with mild-to-moderate AD. 3. To characterize the effect of PF-04360365 on CSF Aβ during dosing for approximately one year.

Critère d'inclusion

mild to moderate Alzheimer's Disease

Liens

euctr
ictrp

Kusajili – Centralise les essais cliniques mondiaux

A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S DI...